OBJECTIVE:To screen and identify endophytic fungi from Schisandra chinensis with antioxidant activity. METH-ODS:The tissue isolation skill was used to isolate endophytic fungi from roots,leaves,stems and fruits of S. chinensis. And anti-oxidant activity of endophytic fungi were screened by DPPH radical scavenging assay and hydroxyl radical scavenging assay. The to-tal DNA were extracted;the 18S rDNA ITS were amplified and sequenced with primer ITS1 and ITS4;the results of sequencing were analyzed comparatively based on homology to confirm the classification of active strains. RESULTS:23 strains were isolated from S. chinensis. GSR-12,isolated from roots of S. chinensis,had strong antioxidant activities. The scavenging rate on DPPH and the hydroxyl radical were 87.96% and 82.31% respectively. GSR-12 strain was identified as Clonostachys rosea by analyzed com-paratively. CONCLUSIONS:1 strain of C. rosea,isolated from roots of S. chinensis,has strong antioxidant activity.

In order to establish a high efficient regeneration system of sunflower, we optimized the process of callus induction, differentiation and rooting by screening the optimum genotype, explant materials, hormone and cytokine concentration and additives. The results indicated that hybrid sunflowers were easier to regenerate than selfing ones; The best explant was four days cotyledon. The optimum induction medium was Murashige and Skoog (MS) + 2.0 mg/L 6-benzyladenine (6-BA) + 0.5 mg/L naphthaleneacetic acid (NAA) + 1.0 mg/L kinetin (KT). The maximum rate of callus induction was 100%. The optimum differentiation medium was MS +0.2 mg/L 6-BA + 0.5 mg/L NAA + 0.3 mg/L KT + 0.3 mg/L silver nitrate (AgNO3) + 0.2 g/L active carbon (AC), and the buds differentiation rate was up to 71%. The best rooting culture medium was 1/2 MS + 0.6 mg/L indolebutyric acid (IBA). The highest rooting rate was 77%. The analysis of variance showed that genotype, explants growth time, different kinds and concentration of hormone, AC concentration had a significant effect on sunflower regeneration.
Cotyledon ; drug effects ; growth & development ; Genotype ; Helianthus ; genetics ; physiology ; Hybridization, Genetic ; Plant Growth Regulators ; pharmacology ; Plant Leaves ; drug effects ; growth & development ; Plant Roots ; drug effects ; growth & development ; Regeneration ; drug effects ; physiology ; Seedlings ; drug effects ; growth & development ; Tissue Culture Techniques

Objective To summary the electroencephalography characteristics of temporal lobe ganglion glioma (GG),and explore the role of electroencephalogram in diagnosis and treatment of temporal lobe GG.Methods Retrospective analysis of clinical features,diagnosis and treatment of 24 patients with temporal lobe GG,admitted to our hospital from September 2008 to September 2015,was performed.The temporal lobe GG electroencephalography features were accepted focused research.Results Break electroencephalography showed that:abnormal discharge of lesions in store area and contralateral brain regions was noted in 17 patients (70.8％).Episodes electroencephalography showed that:10 patients (41.6％) could be conformed that discharge was originated from the side of temporal sphenoid.Intra-operative electroencephalography showed that the medial temporal lobe in 22 patients (91.7％) had low amplitude fast wave with high reflection of sharp wave or spike wave;the temporal lobe cortex in 23 patients (95.8％) had high reflection of sharp wave or spike wave.The patients were followed up for one to 8 years.Engel's grading I was noted in 19 patients (79％),including 11 gradually stopped taking antiepileptic drugs after three years of free seizure;Engel's grading Ⅱ was noted in 5 patie nts (79％),and antiepileptic drugs were taken.Conclusions The temporal lobe GG electroencephalography shows that abnormal discharge is sharp and slow waves are noted,which are easy to generalize to other brain regions and the contralateral side.Monitoring of electroencephalography during operation can record the abnormal discharge around and in the center of GG with spike wave rhythms.Cortical electroencephalogram and deep electrode monitoring can help to determine the lesion and the around range of epilepsy,which can guide the operation and improve the control of seizures.

Background::Transplant renal artery stenosis (TRAS) is a vascular complication after kidney transplantation associated with poor outcomes. This study aimed to analyze the efficacy and safety of low-dose aspirin for preventing TRAS.Methods::After kidney transplantation, patients were enrolled from January 2018 to December 2020 in Henan Provincial People’s Hospital. A total of 351 enrolled recipients were randomized to an aspirin group with low-dose intake of aspirin in addition to standard treatment ( n = 178), or a control group with only standard treatment ( n = 173). The patients was initially diagnosed as TRAS (id-TRAS) by Doppler ultrasound, and confirmed cases were diagnosed by DSA (c-TRAS). Results::In the aspirin and control groups, 15.7% (28/178) and 22.0% (38/173) of the recipients developed id-TRAS, respectively, with no statistical difference. However, for c-TRAS, the difference of incidence and cumulative incidence was statistically significant. The incidence of c-TRAS was lower in the aspirin group compared with the control group (2.8% [5/178] vs. 11.6% [20/173], P = 0.001). Kaplan–Meier estimates and Cox regression model identified the cumulative incidence and hazard ratio (HR) of TRAS over time in two groups, showing that recipients treated with aspirin had a significantly lower risk of c-TRAS than those who were not treated (log-rank P = 0.001, HR = 0.23, 95% confidence interval [CI]: 0.09–0.62). The levels of platelet aggregation rate ( P < 0.001), cholesterol ( P = 0.028), and low-density lipoprotein cholesterol ( P = 0.003) in the aspirin group were decreased compared with the control group in the third-month post-transplantation. For the incidence of adverse events, there was no statistical difference. Conclusion::Clinical application of low-dose aspirin after renal transplant could prevent the development of TRAS with no significant increase in adverse effects.Trial Registration::Clinicaltrials.gov, NCT04260828.